Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of once-weekly and once-monthly CAM2038 (buprenorphine depot) in opioid use disorder
2015-003035-35Phase 3Completed
- Sponsor
- Braeburn Pharmaceuticals
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of CAM2038 in opioid use disorder (OUD), sponsored by Braeburn Pharmaceuticals. Primary endpoint: Primary safety endpoints. Started Aug 2015; status: completed.
02
Drugs
CAM2038
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on 2015-003035-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003035-35.